No more flying blind outside the arterial walls. Unlike coronary angiography, intravascular ultrasound (IVUS) gives you inside knowledge of coronary arteries. Assess plaque type and severity with PCI guidance tools that eliminate guesswork. The result: clearer treatment decisions, fewer future complications, and the best long-term outcomes.
SYNTAX II offers significant improvement in long-term outcomes:
The SYNTAX II1 clinical trial is a landmark study proving that IVUS guidance of coronary arteries and Modern PCI techniques give statistically significant improvement in long-term outcomes, leading to better treatment decisions and a reduction in rates of revascularization, peri-procedural MI, and acute ST.
IVUS guidance lowers MACE post-procedure:
Clinical studies reveal that IVUS-guidance led to the use of larger stents, more post-dilation, additional stenting, or higher pressures in patients, resulting in lower rates of ST, MI, and TLR. Using IVUS vs coronary angiography alone leads to a statistically significant difference in MACE three years post-procedure.
Measuring FFR reduces long-term MI likelihood:
The FAME I & II trials show that using FFR led to statistically significant reduction of cardiac death or MI at 5 years compared to coronary angiography. Measuring FFR can also help identify those for whom the treatment is most appropriate, and lower costs.
1. The SYNTAX II Trial studied the SYNERGY Bioabsorbable Polymer Stent in patients with either CTO or three vessel disease. The SYNTAX I trial studied the TAXUS Express2 drug eluting stent in patients with either Left Main or three vessel disease. Banning, Adrian, MBBS, MD. Clinical outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 5-year results of the SYNTAX II study. ESC Congress 2021.
